

Publikasjoner, Einar Haukås:

1.

Bendamustine plus rituximab for chronic cold agglutinin disease: Results of a Nordic prospective multicenter trial

Sigbjørn Berentsen, Ulla Randen, Markku Oksman, Henrik Birgens, Tor Henrik Anderson Tvedt, Jakob Dalgaard, Eivind Galteland, Einar Haukås, Robert Brudevold, Jon Hjalmar Sørbø, Inger Anne Næss, Agnieszka Malecka, and Geir Erland Tjønnfjord

Blood. Decision: Accept - Submit to First Edition; Decision Date: 15 May 2017. Date Received: 2 May 2017

2.

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

Zwegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A.

Blood. 2016 Mar 3;127(9):1109-16. PMID: 26802176

3.

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group.

Blood. 2013 Jun 6;121(23):4647-54 PMID: 23616624

4.

A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma.

[Vangsted AJ](#), [Nielsen KR](#), [Klausen TW](#), Haukaas E, [Tjønneland A](#), [Vogel U](#). [Br J Haematol](#). 2012 Aug;158(4):515-8 PMID: 22540426

5. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG).

Eur J Haematol. 2012 Jun;88(6):485-96. PMID: 22404182

6. Survival in adults with acute lymphoblastic leukaemia

Tangen JM, Fløisand Y, Haukås E, Naess IA, Skjelbakken T, Stapnes C, Tjønnfjord GE. Tidsskr Nor Laegeforen. 2010 Sep 9;130(17):1710-3. PMID: 20835280

7. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group. Blood. 2010 Sep 2;116(9):1405-12. PMID: 20448107

8. Survival in adults with acute myelogenous leukemia.

Tangen JM, Fløisand Y, Foss-Abrahamsen J, Haukås E, Naess IA, Skjelbakken T. Tidsskr Nor Laegeforen. 2008 May 15;128(10):1164-7. Norwegian. PMID: 18480864

9. **Innsendt t. tidsskrift**

Genetic variations in the promoter region of the genes *NFKB1* and *IL1B* are not associated to outcome of Interferon- α 2b, added to melphalan-prednisone therapy of patients with multiple myeloma a re-analysis of a randomized study

Annette J. Vangsted¹, Einar Haukås², Erik Holmberg³, Jan Westin⁴, Ingemar Turesson⁵, Ilona K Sørensen⁶, Ulla Vogel⁷, Anders Waage⁸ Martin Hjorth⁹